CTIS2023-503531-18-00招募中1 期
Multicentre, open-label, randomised, two-arm, parallel-group, superiority trial to assess bioavailability and practicability of two once-daily tacrolimus formulations, Envarsus® compared with Advagraf™, administered in kidney transplant recipients - TaC:Drop
niversitaetsklinikum Regensburg0 个研究点目标入组 300 人开始时间: 2023年7月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Signed and dated written informed consent, Adult ( = 18 years old) male or female, Renal insufficiency necessitating kidney transplantation and approved to receive a first or second kidney allograft from a living or deceased organ donor, ABO blood type compatible with the donor kidney, Able to swallow an oral formulation of tacrolimus in tablet or capsule form
排除标准
- •Multi-organ transplantation, Planned or foreseeable use of cyclosporine, belatacept or any tacrolimus preparation other than Envarsus® or Advagraf™, Known contraindication or hypersensitivity to tacrolimus, and/or to any of the excipients listed in section 6.1 of the Summary of Product Characteristics (SmPC) of both Envarsus® and Advagraf™, and/or to any other macrolides, Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test, Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless using a highly-effective method of contraception, Participation in another interventional clinical trial in the time period starting from 4 weeks prior to randomisation and throughout the entire trial period, Any condition or factor which, in the judgement of the investigator, would place the subject at undue risk, invalidate communication with the investigator or study team, or hamper compliance with the trial protocol or follow-up schedule, Inability to freely give informed consent (e.g. individuals under legal guardianship), Any previous solid organ transplantation (other than a first kidney allograft), For recipients of a second kidney transplant: loss of first kidney transplant within 2 years after transplantation owing to immunological reasons or recurrence of the underlying renal disease, Patient and/or donor is positive for HCV, HBV or HIV, History of any malignancy that could not be curatively treated, Ongoing abuse of drugs or alcohol, Signs of advanced liver disease or any signs of liver decompensation, Ongoing uncontrolled systemic infection, Severe diarrhoea, vomiting, active peptic ulcer, previous bariatric surgery, or any other gastrointestinal disorder that may affect absorption of tacrolimus
研究者
相似试验
招募中
4 期
Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus® compared with Advagraf® in de novo liver transplant recipients2024-518033-28-00Universitaetsklinikum Regensburg AöR268
进行中（未招募）
2 期
Clinical trial to Evaluate Treatment Compliance, Efficacy and Safety of an Improved new formulation of Deferasirox in the form of Granules in children of the age 2 to 18 Years Old who have Iron overload.CTRI/2017/10/010252ovartis Healthcare Private Limited6
进行中（未招募）
不适用
A randomized, multicenter, open-label, two-arm, parallel, phase III study to evaluate the efficacy and safety of nicotinic acid administered in combination with simvastatin for 6 months in comparison to simvastatin therapy alone in inhibiting the progression of atherosclerosis in patients with carotid arteries stenosis and dyslipidemia.EUCTR2014-003213-29-PLSciencePharma spólka z ograniczona odpowiedzialnoscia sp. j.
进行中（未招募）
1 期
Pharmacokinetics, pharmacodynamics and safety of DEB025/alisporivir in combination with ribavirin therapy in chronic hepatitis C genotype 2 and 3 patients who have previously failed interferon therapy or are intolerant or unable to take interferoChronic hepatitis CMedDRA version: 18.0Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-003751-38-FRovartis Pharma Services AG52
进行中（未招募）
不适用
A study to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab/docetaxel in patients with breast cancer that spread to other tissues.First-line treatment of patients with HER2 negative metastatic breast cancer.MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2006-001365-42-ATF. Hoffmann-La Roche Ltd424